Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.72 |
| ▸ | RARG | P13631 | 11/20 | 0.72 |
| ▸ | RARA | P10276 | 10/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.55 |
| ▸ | RXRA | P19793 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615332 | 1.00 | RARB (0.72) | RARBRARGRARACYP3A4PTPN1 | |
| SCHEMBL1615329 | 1.00 | RARB (0.72) | RARBRARGRARACYP3A4PTPN1 | |
| SCHEMBL8026092 | 0.91 | RARB (0.61) | RARBRARGRARACYP3A4PTPN1 | |
| SCHEMBL9746789 | 0.90 | RARB (0.62) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9187421 | 0.87 | CYP26A1 (0.60) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9187417 | 0.87 | CYP26A1 (0.60) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7876455 | 0.85 | RARA (0.54) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7876451 | 0.85 | RARA (0.54) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL30721644 | 0.85 | RARB (0.74) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL1615305 | 0.84 | RARB (0.74) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923579-B2 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2011-04-12 | — | — | US | disclosed |
| US-7923579-B2 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2011-04-12 | — | — | US | disclosed |
| US-7923579-B2 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2011-04-12 | — | — | US | disclosed |
| EP-1692097-B1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2009-09-02 | — | — | EP | disclosed |
| EP-1692097-B1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | EXONHIT THERAPEUTICS S.A. (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1692097-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | Exonhit Therapeutics SA (FR) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058803-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058803-A1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2005-06-30 | — | — | WO | disclosed |
| EP-1541549-A1 | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods | Exonhit Therapeutics S.A. (FR) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129368-A1 | Tricyclic hydroxamate and benzamide derivatives, compositions and methods | HDAC5, HDAC1, HDAC2 | RARB 998/4885RARG 904/4885RARA 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.